Loading company…
MVRIX develops therapeutic technologies in targeted mRNA delivery, in vivo CAR-T, recombinant botulinum toxins and biologics.
Founded in 2021 and based in Gyeonggi, South Korea, MVRIX develops therapeutics using biotechnology and protein engineering. Its platforms cover targeted mRNA delivery, in vivo CAR-T, recombinant botulinum toxins and biologics. In 2025, it licensed its MBT-002 recombinant botulinum toxin program to Eyegene. The company completed a KRW 8 billion Series B financing in September 2026.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in